Jim Simons Biotechnology

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
PASG Passage Bio, Inc.	$385M	$566,000 0.0% of portfolio	1,416,399	Q2 2025 Added 0.43%
SANA Sana Biotechnology, Inc.	$807M	$556,000 0.0% of portfolio	203,712	Q2 2025 New
PRTA Prothena Corp Public LTD CO	$492M	$547,000 0.0% of portfolio	90,200	Q2 2025 Reduced 62.4%
FULC Fulcrum Therapeutics, Inc.	$405M	$540,000 0.0% of portfolio	78,500	Q2 2025 Reduced 80.43%
URGN Uro Gen Pharma Ltd.	$549M	$523,000 0.0% of portfolio	38,200	Q2 2025 Reduced 57.84%
ELDN Eledon Pharmaceuticals, Inc.	$29.3M	$516,000 0.0% of portfolio	190,673	Q2 2025 Added 55.31%
CRTX Cortexyme, Inc.	$70.5M	$489,000 0.0% of portfolio	379,800	Q2 2025 Reduced 24.03%
PRLD Prelude Therapeutics Inc	$46.2M	$471,000 0.0% of portfolio	581,800	Q2 2025 Reduced 11.41%
PYXS Pyxis Oncology, Inc.	$161M	$459,000 0.0% of portfolio	417,822	Q2 2025 Reduced 28.23%
TARA Protara Therapeutics, Inc.	$60.4M	$452,000 0.0% of portfolio	149,200	Q2 2025 Added 15.3%
ADAP Adaptimmune Therapeutics PLC	$4.9M	$451,000 0.0% of portfolio	1,882,860	Q2 2025 Added 3.8%
NAUT Nautilus Biotechnology, Inc.	$204M	$446,000 0.0% of portfolio	619,906	Q2 2025 Added 106.32%
XNCR Xencor Inc	$888M	$437,000 0.0% of portfolio	55,600	Q2 2025 Reduced 63.52%
FDMT 4 D Molecular Therapeutics, Inc.	$344M	$432,000 0.0% of portfolio	116,553	Q2 2025 Added 496.09%
ALDX Aldeyra Therapeutics, Inc.	$302M	$432,000 0.0% of portfolio	112,800	Q2 2025 Reduced 3.26%
ANTX An2 Therapeutics, Inc.	$23.3M	$422,000 0.0% of portfolio	398,854	Q2 2025 Added 8.18%
BDTX Black Diamond Therapeutics, Inc.	$167M	$414,000 0.0% of portfolio	167,100	Q2 2025 Added 109.14%
IKNA Ikena Oncology, Inc.	$50M	$413,000 0.0% of portfolio	308,856	Q2 2025 Added 4.88%
CRDF Cardiff Oncology, Inc.	$99.2M	$408,000 0.0% of portfolio	129,690	Q2 2025 New
PGEN Precigen, Inc.	$812M	$408,000 0.0% of portfolio	287,403	Q2 2025 Reduced 63.75%
CLSD Clearside Biomedical, Inc.	$228M	$397,000 0.0% of portfolio	496,589	Q2 2025 Reduced 10.45%
CHRS Coherus Bio Sciences, Inc.	$105M	$381,000 0.0% of portfolio	522,925	Q2 2025 Added 2.41%
EYPT Eye Point Pharmaceuticals, Inc.	$398M	$348,000 0.0% of portfolio	37,000	Q2 2025 Reduced 68.46%
HOWL Werewolf Therapeutics, Inc.	$34M	$344,000 0.0% of portfolio	316,300	Q2 2025 Added 394.99%
CYTK Cytokinetics Inc	$6.26B	$335,000 0.0% of portfolio	10,167	Q2 2025 Reduced 91.57%
TNGX Tango Therapeutics, Inc.	$686M	$335,000 0.0% of portfolio	65,500	Q2 2025 Reduced 62.46%
RNXT Renovo Rx, Inc.	$9.7M	$332,000 0.0% of portfolio	251,800	Q2 2025 Added 810.47%
ORMP Oramed Pharmaceuticals Inc.	$93.2M	$324,000 0.0% of portfolio	144,200	Q2 2025 Added 1.19%
NVCT Nuvectis Pharma, Inc.	$88.7M	$321,000 0.0% of portfolio	43,000	Q2 2025 New
BCAB Bio Atla, Inc.	$25.4M	$301,000 0.0% of portfolio	754,243	Q2 2025 Added 1.26%
XOMA Xoma Corp	$393M	$299,000 0.0% of portfolio	11,900	Q2 2025 Reduced 13.14%
FHTX Foghorn Therapeutics Inc.	$185M	$294,000 0.0% of portfolio	62,636	Q2 2025 Added 9.43%
ATNM Actinium Pharmaceuticals, Inc.	$33.2M	$293,000 0.0% of portfolio	209,501	Q2 2025 Added 263.72%
ABOS Acumen Pharmaceuticals, Inc.	$77.8M	$286,000 0.0% of portfolio	246,588	Q2 2025 Reduced 3.94%
LTRN Lantern Pharma Inc.	$38.3M	$286,000 0.0% of portfolio	90,600	Q2 2025 Added 2.03%
XENE Xenon Pharmaceuticals Inc.	$2.49B	$269,000 0.0% of portfolio	8,600	Q2 2025 Reduced 94.44%
VXRT Vaxart, Inc.	$46.8M	$268,000 0.0% of portfolio	597,443	Q2 2025 New
OLMA Olema Pharmaceuticals, Inc.	$325M	$250,000 0.0% of portfolio	58,800	Q2 2025 Reduced 8.98%
NRIX Nurix Therapeutics, Inc.	$606M	$249,000 0.0% of portfolio	21,900	Q2 2025 Reduced 63.19%
BLTE Belite Bio, Inc	$2.63B	$248,000 0.0% of portfolio	4,300	Q2 2025 New
GLSI Greenwich Life Sciences, Inc.	$109M	$247,000 0.0% of portfolio	27,300	Q2 2025 Added 118.4%
PROK Prokidney Corp Ord Shs Cl A(Cy	$178M	$242,000 0.0% of portfolio	411,645	Q2 2025 Added 159.71%
CNTX Context Therapeutics Inc.	$19M	$240,000 0.0% of portfolio	363,930	Q2 2025 Reduced 14.47%
FATE Fate Therapeutics Inc	$109M	$240,000 0.0% of portfolio	214,463	Q2 2025 New
RZLT Rezolute, Inc.	$390M	$235,000 0.0% of portfolio	52,833	Q2 2025 Reduced 86.05%
MNOV Medicinova Inc	$78.5M	$234,000 0.0% of portfolio	178,700	Q2 2025 Reduced 1.65%
PLRX Pliant Therapeutics, Inc.	$80.8M	$231,000 0.0% of portfolio	199,948	Q2 2025 Added 31.11%
NXTC Next Cure, Inc.	$238M	$230,000 0.0% of portfolio	500,935	Q2 2025 Added 4.37%
IOBT Io Biotech, Inc.	$24.8M	$193,000 0.0% of portfolio	139,300	Q2 2025 Added 10.21%
CABA Cabaletta Bio, Inc.	$71.7M	$191,000 0.0% of portfolio	126,100	Q2 2025 Added 1,056.88%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account